Artificial Intelligence able to identify potentially life-saving antibiotics
A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University Hospital Basel and the Basel-based Department of Biosystems Science and Engineering at the Swiss Federal Institute of Technology in Zurich will initially put their new method to the test as part of a clinical trial.
Study leader Prof. Adrian Egli with his colleague Aline Cuénod in the laboratory medicine department of the University Hospital Basel (img: USB)
Researchers from University Hospital Basel (USB) and the Department of Biosystems Science and Engineering (D-BSSE) at the Swiss Federal Institute of Technology in Zurich (ETH) in Basel are using innovative computer algorithms in the fight against antibiotic-resistant bacteria. With this new method, the researchers can identify characteristics of antibiotic resistance in germs up to 24 hours earlier. This means that it is clear sooner rather than later which antibiotics can still help patients. The cantons of Basel-Stadt and Basel-Landschaft offered financial support for this research project.
“In cases of severe infection, the time until optimal therapy can be the difference between life and death. A quick and precise diagnosis is extremely important here”, comments Professor Adrian Egli, Head of the Clinical Bacteriology department at USB and study director, in a press release.
Larger clinical study will follow
The study team linked 300,000 mass spectrometry data samples from individual bacteria from four laboratories in north-western Switzerland with the results of antibiotic resistance tests in the laboratory. “Intelligent computer algorithms look for patterns in the data that distinguish bacteria with and without resistance from one another”, explains Caroline Weis, PhD student at the D-BSSE at ETH Zurich in Basel and lead author of the study.
The researchers have published their method in the latest edition of the specialist journal “Nature Medicine”. It must now be confirmed in a larger clinical study carried out as part of everyday hospital operations. Plans are already in place for this to take place at USB.
Share this article
You may also be interested in
How Moderna is growing in Switzerland
The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...Read More
Sandoz decides on Basel for headquarters
Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...Read More
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...Read More
University of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...Read More
Rami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...Read More
Basel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....Read More